[go: up one dir, main page]

ES2070276T3 - Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2. - Google Patents

Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2.

Info

Publication number
ES2070276T3
ES2070276T3 ES90304290T ES90304290T ES2070276T3 ES 2070276 T3 ES2070276 T3 ES 2070276T3 ES 90304290 T ES90304290 T ES 90304290T ES 90304290 T ES90304290 T ES 90304290T ES 2070276 T3 ES2070276 T3 ES 2070276T3
Authority
ES
Spain
Prior art keywords
lactons
called
cell growth
macrocyclic
combretastatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90304290T
Other languages
English (en)
Inventor
George R Pettit
Sheo Bux Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arizona
Arizona State University ASU
Original Assignee
University of Arizona
Arizona State University ASU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arizona, Arizona State University ASU filed Critical University of Arizona
Application granted granted Critical
Publication of ES2070276T3 publication Critical patent/ES2070276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Detergent Compositions (AREA)
  • Lubricants (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTA EL AISLAMIENTO Y ELUCIDACION DE NUEVAS LACTONAS MACROCICLICAS DENOMINADAS "COMBRETASTINA D-1" Y "COMBRETASTINA D2", CADA UNA DE LAS CUALES SE HA ENCONTRADO QUE POSEE PROPIEDADES INESPERADAS DE INHIBICION DEL CRECIMIENTO CELULAR. LAS LACTONAS TIENEN LA FORMULA ESTRUCTURAL (I).
ES90304290T 1989-04-26 1990-04-20 Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2. Expired - Lifetime ES2070276T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/344,005 US4940726A (en) 1989-04-26 1989-04-26 Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2

Publications (1)

Publication Number Publication Date
ES2070276T3 true ES2070276T3 (es) 1995-06-01

Family

ID=23348618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90304290T Expired - Lifetime ES2070276T3 (es) 1989-04-26 1990-04-20 Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2.

Country Status (8)

Country Link
US (1) US4940726A (es)
EP (1) EP0397336B1 (es)
JP (1) JP2929025B2 (es)
AT (1) ATE120193T1 (es)
CA (1) CA2010886A1 (es)
DE (1) DE69017946T2 (es)
DK (1) DK0397336T3 (es)
ES (1) ES2070276T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3919255A1 (de) * 1989-06-13 1990-12-20 Bayer Ag Dibenzo/1,5/dioxocin-5-one-derivate, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5393897A (en) * 1993-07-02 1995-02-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structure of spongistatins 5,7,8 and 9
AU776511B2 (en) 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
CN101073668A (zh) 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CA2491310C (en) 2002-07-15 2015-10-06 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
US20040052868A1 (en) * 2002-09-12 2004-03-18 William Asiedu Composition treating for AIDS and associated conditions
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US20090017140A1 (en) * 2007-07-09 2009-01-15 Peter Koepke Maytenus abenfolia extract and methods of extracting and using such extract
US20090035395A1 (en) * 2007-08-01 2009-02-05 Peter Koepke Spondias mombin l. extract and methods of extracting and using such extract
US7879369B2 (en) * 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
KR20100102110A (ko) 2007-11-09 2010-09-20 페레그린 파마수티컬즈, 인크 항-ｖｅｇｆ 항체 조성물 및 방법
PT2219451E (pt) 2007-11-21 2015-02-09 Oxigene Inc Processo para o tratamento de neoplasmas hematopoiéticos
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US20180030095A1 (en) 2015-02-13 2018-02-01 George Robert Pettit Silstatin compounds
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708962A (en) * 1984-12-17 1987-11-24 Harbor Branch Oceanographic Institution, Inc. Antiviral and antitumor cyclohexadienone compositions

Also Published As

Publication number Publication date
US4940726A (en) 1990-07-10
JPH02295986A (ja) 1990-12-06
CA2010886A1 (en) 1990-10-26
JP2929025B2 (ja) 1999-08-03
EP0397336B1 (en) 1995-03-22
EP0397336A2 (en) 1990-11-14
EP0397336A3 (en) 1991-03-27
DK0397336T3 (da) 1995-06-06
ATE120193T1 (de) 1995-04-15
DE69017946D1 (de) 1995-04-27
DE69017946T2 (de) 1995-09-14

Similar Documents

Publication Publication Date Title
ES2070276T3 (es) Lactonas macrociclicas inhibidoras del crecimiento celular denominadas combretastatina d-2.
ES2178036T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que le contienen.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
DK0559743T3 (da) Nye hydroxamsyre- og N-hydroxyurinstofderivater og deres anvendelse
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
DK0726899T3 (da) Nye pyrazincarboxamidderivater, deres fremstilling og deres anvendelse i lægemidler
DK1167354T3 (da) Racemisk huperzin A
DK0497816T3 (da) Behandling af HIV-infektioner og forbindelser anvendelige derved
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
KR910005876A (ko) 모세혈관 취약증의 치료를 위한 극소용 약학적 조성물
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
YU6396A (sh) Kombinacija inhibitora hiv proteaze sa drugim jedinjenjima za terapiju hiv infekcija
RU2001120358A (ru) Применение ингибиторов натрий-водород-антипортера для получения лекарственного средства для ингибирования обусловленных возрастом дисфункций органов, обусловленных возрастом заболеваний и для продления жизни
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
IT7819638A0 (it) Vite autofilettante nonche'procedimento per la sua fabbricazione e ganascia di cilindratura per l'attuazione del procedimento.
ES2076440T3 (es) Oasomicinas, procedimiento para su preparacion y su utilizacion.
DE50311517D1 (de) Cycloglycane geeignet zur verhinderung der infektion von säugetierzellen
ATE232727T1 (de) Kombinationen von hiv-protease inhibitoren
ES2073919T3 (es) Derivados de piperidina 1,3,4-trisubstituidos, su obtencion y empleo.
MX9304283A (es) Derivados de tiadiazinona, procedimiento para su preparacion y preparacion farmaceutica que los con tienen.
SE8704049D0 (sv) Novel pharmacological compounds
ES2059879T3 (es) Compuestos sn-198c fisiologicamente activos y metodo y bacterias para su produccion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 397336

Country of ref document: ES